MGMT and glioblastoma: Currently, the most widely used prognostic factor in GBM is the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter [7] MGMT promoter methylation silences its expression and is associated with longer overall survival in GBM patients, for example, as predictive factor of response to the TMZ treatment.